Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr

Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr

By: IPP Bureau

Last updated : October 28, 2024 11:51 am



Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024


Strides Pharma Science Limited has reported consolidated financial results for the period ended September 30, 2024.

Strides Pharma Science has posted net profit of Rs. 93.23 crores for the period ended September 30, 2024 as against net profit of Rs. 70.20 crores for the period ended June 30, 2024. The company has posted net loss of Rs. 131.34 crores for the period ended September 30, 2023.

Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024 as compared to Rs. 1,100.22 crores during the period ended June 30, 2024. The company has reported total income of Rs.1035.275 crores during the period ended September 30, 2023.

For the Half Year ended Sept 30, 2024, Strides Pharma Science has reported total income of Rs. 2,329.74 crores as compared to Rs.1973.914 crores during the 6 Months period ended September 30, 2023.

The company has posted net profit of Rs. 163.43 crores for the 6 months period ended September 30, 2024 as against net loss of Rs. 138.45 crores for the 6 months period ended September 30, 2023.

Strides Pharma Science Limited

First Published : October 28, 2024 12:00 am